ArticleOpen forum infectious diseases2026
A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the impact of gender has been identified a priority focus in regional and global efforts to eliminate hepatitis C virus (HCV) as a public health threat. Gender affects health and wellness across the lifespan, and women and gender-diverse peoples face increasing structural barriers, leading to a higher risk of HCV acquisition and decreasing the ability to seek care and treatment. The objective of this study was to describe a Canadian cohort of individuals engaged in HCV care self-identified as cis or trans women or trans men. In this cohort of cis women and trans persons, fibrosis scores were low, but specific groups were more likely to have compensated/decompensated cirrhosis, highlighting the need for earlier case-finding and treatment. In addition, opioid agonist therapy (OAT) uptake was poor, an observation that may support co-localizing HCV treatment with OAT initiation to prevent drug use relapse and reinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.